Open AccessTargeting the Hypoxia‐Sensing Pathway in Clinical Hematology
Author(s) -
Forristal Catherine E.,
Levesque Jean-Pierre
Publication year - 2014
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0134
Subject(s) - erythropoietin , haematopoiesis , hypoxia inducible factors , hypoxia (environmental) , plerixafor , hematology , stem cell , hematopoietic growth factor , bone marrow , cancer research , transplantation , granulocyte colony stimulating factor , biology , erythropoiesis , pharmacology , medicine , immunology , microbiology and biotechnology , chemistry , anemia , biochemistry , oxygen , chemotherapy , inflammation , chemokine , organic chemistry , cxcr4 , gene
The importance of hypoxia and hypoxia‐inducible factors (HIFs) in the hematopoietic environment is becoming increasingly recognized. Recent findings show that stabilization of HIF‐1α increases erythropoietin production, HSC quiescence and HSC mobilization in response to granulocyte colony‐stimulating factor. This suggests that PHD inhibitors could be useful agents to reduce anemia in chronic kidney disease patients, protect HSC from accidental irradiation and increase mobilization success in patients requiring transplantation. These findings highlight the importance of the hypoxia‐sensing pathway and HIFs in clinical hematology.